Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Congress Asset Management Co.

Congress Asset Management Co. raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,348,867 shares of the medical equipment provider's stock after purchasing an additional 145,297 shares during the period. Congress Asset Management Co. owned 0.58% of Hologic worth $109,879,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its stake in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Hologic by 21.6% during the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider's stock worth $188,243,000 after acquiring an additional 450,190 shares in the last quarter. Black Creek Investment Management Inc. increased its stake in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock valued at $172,780,000 after acquiring an additional 124,739 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Hologic by 4.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider's stock worth $168,666,000 after purchasing an additional 87,176 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

HOLX traded down $0.28 on Thursday, hitting $80.87. 1,564,924 shares of the stock were exchanged, compared to its average volume of 1,572,439. The business has a 50-day moving average of $80.94 and a two-hundred day moving average of $77.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The firm has a market capitalization of $18.87 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 2.96 and a beta of 0.98. Hologic, Inc. has a 12 month low of $65.55 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company's revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.93 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several analyst reports. Stephens reissued an "overweight" rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Citigroup cut shares of Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Mizuho increased their price objective on shares of Hologic from $85.00 to $90.00 and gave the stock an "outperform" rating in a research report on Friday, October 4th. JPMorgan Chase & Co. increased their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an "overweight" rating in a report on Tuesday, July 30th. Finally, Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $87.50.

Insider Activity

In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company's stock, valued at $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.75% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.